AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23332511 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 29
Study 23332511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 21296694 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeda Vero cell rabies vaccine (Group A)
Number of subjects: 250
Study 21296694 — intervention group
Group type: COMPARATOR
Intervention: Verorab Vero cell rabies vaccine (Group B)
Number of subjects: 250
Study 18675569 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alpha-lipoic acid (ALA) 400 mg
Number of subjects: 66
Study 18675569 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (400 mg) plus vitamins
Number of subjects: 66
Study 18675569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 66
Study 16893702 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted cardioverter defibrillator therapy
Number of subjects: 0
Study 16893702 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 15254792 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine (DEC) 101+/−39 mg
Number of subjects: 25
Study 15254792 — intervention group
Group type: COMPARATOR
Intervention: levodopa 369+/−51 mg
Number of subjects: 25
Study 15254792 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC
Number of subjects: 25
Study 15254792 — intervention group
Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 25
Study 11766830 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GH (2 IU daily) for a minimum of 12 weeks
Number of subjects: 50
Study 11766830 — intervention group
Group type: COMPARATOR
Intervention: Placebo for a minimum of 12 weeks
Number of subjects: 50
Study 9415571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour infusion of OKT3
Number of subjects: 18
Study 9415571 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus infusion of OKT3
Number of subjects: 18
Study 8257887 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg/day
Number of subjects: 338
Study 8257887 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg/day
Number of subjects: 338
Study 8257887 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine early treatment
Number of subjects: 338
Study 3899005 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 40
Study 3899005 — intervention group
Group type: COMPARATOR
Intervention: ticarcillin and tobramycin
Number of subjects: 40
Study 31398997 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of dry extract of ginger (5% active ingredient) three times per day for three months
Number of subjects: 107
Study 31398997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose) three times per day for three months
Number of subjects: 107
Study 31398997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ginger and placebo
Number of subjects: 107
Study 29524509 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 26961775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MWT
Number of subjects: 26
Study 26961775 — intervention group
Group type: COMPARATOR
Intervention: 6MWT
Number of subjects: 26
Study 25457929 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management plus instructions in cognitive-behavioral therapy (CBT)
Number of subjects: 124
Study 25457929 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management plus full CBT
Number of subjects: 124
Study 25457929 — intervention group
Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 124
Study 22955172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (single doses of 5-400 mg)
Number of subjects: 58
Study 22955172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide with high-fat meal
Number of subjects: 58
Study 22955172 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide without regard to food
Number of subjects: 58
Study 20452305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar lordosis brace
Number of subjects: 11
Study 20452305 — intervention group
Group type: COMPARATOR
Intervention: No lumbar lordosis brace
Number of subjects: 11
Study 18076267 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of sleep loss
Number of subjects: 9
Study 18076267 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 9
Study 16101369 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable membrane
Number of subjects: 18
Study 16101369 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 18
Study 12435003 — intervention group
Group type: EXPERIMENTAL
Intervention: Various disinfecting solutions
Number of subjects: 32
Study 12435003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disinfecting solution)
Number of subjects: 32
Study 10074977 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 194
Study 10074977 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 194
Study 9987734 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) with hMG/hCG and DIPI
Number of subjects: 65
Study 9987734 — intervention group
Group type: COMPARATOR
Intervention: hMG/hCG without GnRHa
Number of subjects: 65
Study 1807428 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention delivered by nurses on diet and health
Number of subjects: 88
Study 1807428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 88
Study 6853264 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) administered orally at a dose of 3.0g/m2 and intravesically at a dose of 1.0g
Number of subjects: 22
Study 6853264 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (retrospective study)
Number of subjects: 22
Study 31533845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (IPT with dihydroartemisinin-piperaquine)
Number of subjects: 10079
Study 31533845 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10079
Study 29796786 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed opportunities for HIV testing
Number of subjects: 5012
Study 29796786 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional testing settings
Number of subjects: 5012
Study 29796786 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-traditional testing settings
Number of subjects: 5012
Study 29796786 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants positive for HIV at baseline
Number of subjects: 5012
Study 26955859 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171
Study 26955859 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14171
Study 26955859 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 14171
Study 26955859 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 14171
Study 26955859 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple characteristics (decreasing creatinine clearance, COPD, male sex, peripheral vascular disease, diabetes)
Number of subjects: 14171
Study 25533338 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackmores® Executive B Stress Formula
Number of subjects: 200
Study 25533338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 22260826 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral solution (group II)
Number of subjects: 75
Study 22260826 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral solution (group III)
Number of subjects: 75
Study 22260826 — intervention group
Group type: COMPARATOR
Intervention: Parenteral solution (group IV)
Number of subjects: 75
Study 20605499 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d soy isoflavones
Number of subjects: 242
Study 20605499 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/d soy isoflavones
Number of subjects: 242
Study 20605499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 18653341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline infusion
Number of subjects: 0
Study 18653341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenic protein-2 (rhBMP-2)
Number of subjects: 0
Study 16479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of rhBMP-2
Number of subjects: 0
Study 12365323 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, fromilid (clarithromycin), and metronidazole for 7 days followed by omeprazole for 2 weeks
Number of subjects: 20
Study 12365323 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, fromilid (clarithromycin), and furazolidone for 7 days followed by omeprazole for 2 weeks
Number of subjects: 20
Study 10872363 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-wedge high tibial osteotomy (HTO)
Number of subjects: 46
Study 10872363 — intervention group
Group type: COMPARATOR
Intervention: Open-wedge procedure based on the hemicallotasis technique (HCO)
Number of subjects: 46
Study 10872363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical results evaluated on Hospital for Special Surgery, Lysholm and Wallgren‐Tegner activity scores
Number of subjects: 46
Study 8950072 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis treatment
Number of subjects: 0
Study 8950072 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolemic subjects
Number of subjects: 0
Study 8950072 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypercholesterolemic patients
Number of subjects: 0
Study 1757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.05% cream
Number of subjects: 0
Study 1757613 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 6753643 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, 0.07 mg/kg (group M, 31 patients)
Number of subjects: 100
Study 6753643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 1.0 mg/kg (group H, 34 patients)
Number of subjects: 100
Study 6753643 — intervention group
Group type: COMPARATOR
Intervention: Midazolam diluent as a placebo (group P, 35 patients)
Number of subjects: 100
Study 31306077 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary incisor intrusion arch
Number of subjects: 32
Study 31306077 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat anterior bite plate
Number of subjects: 32
Study 28732480 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.d.)
Number of subjects: 100
Study 28732480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26368559 — intervention group
Group type: EXPERIMENTAL
Intervention: Female infants
Number of subjects: 582
Study 26368559 — intervention group
Group type: EXPERIMENTAL
Intervention: Women pregnant with female fetuses
Number of subjects: 582
Study 26368559 — intervention group
Group type: EXPERIMENTAL
Intervention: Female fetuses
Number of subjects: 582
Study 24120713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 100 μg FPNS
Number of subjects: 20
Study 24120713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 400 μg FPNS
Number of subjects: 20
Study 24120713 — intervention group
Group type: COMPARATOR
Intervention: 2 × 100 μg FPNS
Number of subjects: 20
Study 24120713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 100 μg FPNS and 1 × 400 μg FPNS
Number of subjects: 20
Study 24120713 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 20
Study 21283921 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream (two-week cycle)
Number of subjects: 121
Study 21283921 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream (two-week cycle)
Number of subjects: 121
Study 21283921 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream (three-week cycle)
Number of subjects: 121
Study 21283921 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream (three-week cycle)
Number of subjects: 121
Study 19042940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract (500 mg)
Number of subjects: 137
Study 19042940 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (100 mg)
Number of subjects: 137
Study 18001442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 156
Study 18001442 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream
Number of subjects: 156
Study 18001442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clindamycin
Number of subjects: 156
Study 18001442 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal suppositories
Number of subjects: 156
Study 15449205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 0
Study 15449205 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 0
Study 11581566 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training regimens differing in dose (kcal.wk‐1) and/or intensity (relative to peak VO2)
Number of subjects: 384
Study 11581566 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 384
Study 9822463 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic oophorectomy
Number of subjects: 25
Study 7926102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic methotrexate
Number of subjects: 0
Study 7926102 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser laparoscopic salpingotomy
Number of subjects: 0
Study 2340210 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (40 mg)
Number of subjects: 10
Study 2340210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7404209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular ketamine and hyaluronidase
Number of subjects: 0
Study 31915163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin
Number of subjects: 220
Study 31915163 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cephalosporin
Number of subjects: 220
Study 30252088 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived character strengths
Number of subjects: 171
Study 30252088 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of leaders' character strengths
Number of subjects: 171
Study 30252088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignment with Australian Army core values
Number of subjects: 171
Study 28674125 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-determination group training (GSD-GT)
Number of subjects: 178
Study 28674125 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control Group)
Number of subjects: 178
Study 25766118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 25766118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with 75% cost reduction
Number of subjects: 0
Study 23391851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (parent and student intervention)
Number of subjects: 3490
Study 23391851 — intervention group
Group type: COMPARATOR
Intervention: Parent intervention
Number of subjects: 3490
Study 23391851 — intervention group
Group type: COMPARATOR
Intervention: Student intervention
Number of subjects: 3490
Study 23391851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3490
Study 21184975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkins diet (n=70)
Number of subjects: 311
Study 19291119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injections of 75 microg of Heberprot‐P three times per week up to complete wound healing
Number of subjects: 20
Study 17522570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) followed by intravenous NTG (up to 80 microg/min)
Number of subjects: 34
Study 17522570 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by intravenous NTG (up to 160 microg/min)
Number of subjects: 34
Study 15056579 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus mood stabiliser (lithium or valproate)
Number of subjects: 0
Study 15056579 — intervention group
Group type: COMPARATOR
Intervention: Mood stabiliser alone (lithium or valproate)
Number of subjects: 0
Study 11788176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy (continuous conjugated equine estrogens (CEE) ‐ 0.625mg per day)
Number of subjects: 40
Study 11788176 — intervention group
Group type: COMPARATOR
Intervention: Transdermal therapy (patches delivering continuous 17beta‐estradiol (E2)‐‐0.05mg per day)
Number of subjects: 40
Study 11788176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral CEE and transdermal E2)
Number of subjects: 40
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients on day 1
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients on day 3
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients on day 14
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients on day 21
Number of subjects: 134
Study 9711425 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients on day of admission
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients on day 3
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients on day 7
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients on day 14
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients on day 21
Number of subjects: 134
Study 9711425 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated healing patients (both burn and trauma)
Number of subjects: 134
Study 7989945 — intervention group
Group type: COMPARATOR
Intervention: FAM (fluorouracil, doxorubicin, and mitomycin)
Number of subjects: 130
Study 7989945 — intervention group
Group type: EXPERIMENTAL
Intervention: PELF (cisplatin, epirubicin, and leucovorin preceding fluorouracil)
Number of subjects: 130
Study 7989945 — intervention group
Group type: COMPARATOR
Intervention: FAM
Number of subjects: 130
Study 7989945 — intervention group
Group type: EXPERIMENTAL
Intervention: PELF
Number of subjects: 130
Study 2731120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5‐Fluorouracil, and prednisone (CFP)
Number of subjects: 182
Study 2731120 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP, methotrexate, and vincristine (CFPMV)
Number of subjects: 182
Study 2731120 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 182
Study 2731120 — intervention group
Group type: EXPERIMENTAL
Intervention: ER- patients
Number of subjects: 182
Study 2731120 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+ patients
Number of subjects: 182
Study 55532 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol
Number of subjects: 15
Study 31286818 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet drinkers (N=39)
Number of subjects: 550
Study 31286818 — intervention group
Group type: COMPARATOR
Intervention: Non-drinking counterparts (N=39)
Number of subjects: 550
Study 29151313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 physical therapy sessions (Group 10)
Number of subjects: 60
Study 29151313 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 physical therapy sessions (Group 15)
Number of subjects: 60
Study 25560809 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 422
Study 25560809 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 422
Study 23610200 — intervention group
Group type: EXPERIMENTAL
Intervention: Early review and use of cough algorithm (early-arm)
Number of subjects: 272
Study 23610200 — intervention group
Group type: COMPARATOR
Intervention: Usual care until review and use of cough algorithm (delayed-arm)
Number of subjects: 272
Study 20716625 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet SCA
Number of subjects: 122
Study 20716625 — intervention group
Group type: COMPARATOR
Intervention: Paper SCA
Number of subjects: 122
Study 19776222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158
Study 19776222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 158
Study 16741298 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDOPA PET
Number of subjects: 81
Study 16741298 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG PET
Number of subjects: 81
Study 15584808 — intervention group
Group type: EXPERIMENTAL
Intervention: Practiced high-demand problems (practiced 50 times)
Number of subjects: 0
Study 15584808 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequently practiced high-demand problems (practiced 1 or 2 times)
Number of subjects: 0
Study 15584808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure test on practiced problems
Number of subjects: 0
Study 15584808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpracticed problems with heavy working memory demands
Number of subjects: 0
Study 11331718 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour workshop on violence prevention (intervention group)
Number of subjects: 56
Study 11331718 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulatory clinic manual with articles on violence prevention (control group)
Number of subjects: 56
Study 9014954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) during rehabilitation
Number of subjects: 28
Study 9014954 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation services
Number of subjects: 28
Study 9014954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 28